Why a potent cancer drug discovered in Italian soil earned the name Red Devil.
In short: Doxorubicin is a cornerstone of modern chemotherapy, yet its clinical utility is shadowed by a severe, dose-dependent risk of heart failure. Known colloquially as the red devil due to its vivid pigment and harsh side effects, this compound remains a vital, albeit dangerous, weapon against a wide range of cancers.
Discovered in the 1950s by Farmitalia Research Laboratories, doxorubicin originated from a soil sample collected near the 13th-century Castel del Monte in Italy. Researchers isolated a red-pigmented antibiotic from the bacterium Streptomyces peucetius, which showed promise against tumors in mice. The drug was initially developed alongside daunorubicin, but doxorubicin proved more effective against solid tumors. It gained FDA approval in 1974 and is now listed on the World Health Organization's List of Essential Medicines.
The drug functions by intercalating into DNA, where it stabilizes the topoisomerase II enzyme complex. This prevents the DNA double helix from re-ligating after being broken for replication, effectively halting cell division. While this mechanism is lethal to cancer cells, it also triggers significant collateral damage. The most feared complication is dilated cardiomyopathy, a condition where all four heart chambers enlarge, leading to systolic and diastolic dysfunction. This heart failure carries a 50% mortality rate, and as of 2010, no effective treatment for established doxorubicin-induced cardiomyopathy exists.
To mitigate these risks, researchers developed liposomal formulations like Doxil and Myocet, which encapsulate the drug to reduce cardiotoxicity. However, these versions introduce their own challenges, such as palmar plantar erythrodysesthesia, or hand-foot syndrome, characterized by painful skin eruptions. Despite these hurdles, ongoing research explores new delivery methods, including nanoporous optical antennas and immunoconjugates, aiming to harness the drug's potent anti-cancer activity while sparing healthy tissue from its systemic toxicity.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Doxorubicin
To cite this card, link to https://intellectplus.co.uk/app/science-doxorubicin.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicines · More in Health · Latest · A–Z · All topics